BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-esc-2026-level-ph-hfpef-latebreaker@catalyst-calendar.local
DTSTAMP:20260720T200526Z
DTSTART:20260828T070000Z
DTEND:20260828T073000Z
SUMMARY:ESC 2026心血管大会LEVEL三期PH-HFpEF late-breaking数据窗口
DESCRIPTION:ESC Congress 2026将于2026-08-28至2026-08-31在慕尼黑举行；Tenax披露其TNX-103口服levosimendan治疗PH-HFpEF的registrational Phase 3 LEVEL研究将在late-breaking clinical science环节展示，且公司预计8月报告topline结果。\\nImpact score: 62\\nExpected: LEVEL数据将验证PH-HFpEF治疗中口服levosimendan的疗效和安全性，可能影响心衰/肺高压未满足需求赛道。\\nAffected: TENX(subject\, unknown\, score 86)\; JNJ(peer\, mixed\, score 35)\; XBI(etf\, mixed\, score 34)\\nSources: ESC Congress 2026 official page: https://www.escardio.org/events/congresses/esc-congress/\\nTenax LEVEL late-breaking release: https://investors.tenaxthera.com/news-releases/news-release-details/tenax-therapeutics-announces-late-breaking-presentation-level\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-esc-2026-level-ph-hfpef-latebreaker
CATEGORIES:conference\,US\,ESC\,cardiology\,Phase 3\,late-breaking\,PH-HFpEF
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: ESC 2026心血管大会LEVEL三期PH-HFpEF late-breaking数据窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: ESC 2026心血管大会LEVEL三期PH-HFpEF late-breaking数据窗口
END:VALARM
END:VEVENT
END:VCALENDAR